Cargando…
Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer
In Denmark, patients with serious nonspecific symptoms and signs of cancer (NSSC) are referred to the diagnostic outpatient clinics (DOCs) where an accelerated cancer diagnostic program is initiated. Various immunological and inflammatory biomarkers have been associated with cancer, including solubl...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518177/ https://www.ncbi.nlm.nih.gov/pubmed/28393357 http://dx.doi.org/10.1002/ijc.30732 |
_version_ | 1783251442071502848 |
---|---|
author | Rasmussen, Line Jee Hartmann Schultz, Martin Gaardsting, Anne Ladelund, Steen Garred, Peter Iversen, Kasper Eugen‐Olsen, Jesper Helms, Morten David, Kim Peter Kjær, Andreas Lebech, Anne‐Mette Kronborg, Gitte |
author_facet | Rasmussen, Line Jee Hartmann Schultz, Martin Gaardsting, Anne Ladelund, Steen Garred, Peter Iversen, Kasper Eugen‐Olsen, Jesper Helms, Morten David, Kim Peter Kjær, Andreas Lebech, Anne‐Mette Kronborg, Gitte |
author_sort | Rasmussen, Line Jee Hartmann |
collection | PubMed |
description | In Denmark, patients with serious nonspecific symptoms and signs of cancer (NSSC) are referred to the diagnostic outpatient clinics (DOCs) where an accelerated cancer diagnostic program is initiated. Various immunological and inflammatory biomarkers have been associated with cancer, including soluble urokinase plasminogen activator receptor (suPAR) and the pattern recognition receptors (PRRs) pentraxin‐3, mannose‐binding lectin, ficolin‐1, ficolin‐2 and ficolin‐3. We aimed to evaluate these biomarkers and compare their diagnostic ability to classical biomarkers for diagnosing cancer in patients with NSSC. Patients were included from the DOC, Department of Infectious Diseases, Copenhagen University Hospital Hvidovre. Patients were given a final diagnosis based on the combined results from scans, blood work and physical examination. Weight loss, Charlson score and previous cancer were registered on admission, and plasma concentrations of biomarkers were measured. The primary outcome was incident cancer within 1 year. Out of 197 patients included, 39 patients (19.8%) were diagnosed with cancer. Patients with cancer were significantly older and had a higher burden of comorbidities and previous cancer diagnoses compared to patients who were not diagnosed with cancer. Previous cancer, C‐reactive protein (CRP) and suPAR were significantly associated with newly diagnosed cancer during follow‐up in multiple logistic regression analyses adjusted for age, sex and CRP. Neither any of the PRRs investigated nor self‐reported weight loss was associated with cancer. In this study, previous cancer, CRP and suPAR were significantly associated with cancer diagnosis in patients with NSSC. Ficolin‐1‐3, MBL and pentraxin‐3 were not associated with cancer. |
format | Online Article Text |
id | pubmed-5518177 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-55181772017-08-03 Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer Rasmussen, Line Jee Hartmann Schultz, Martin Gaardsting, Anne Ladelund, Steen Garred, Peter Iversen, Kasper Eugen‐Olsen, Jesper Helms, Morten David, Kim Peter Kjær, Andreas Lebech, Anne‐Mette Kronborg, Gitte Int J Cancer Tumor Markers and Signatures In Denmark, patients with serious nonspecific symptoms and signs of cancer (NSSC) are referred to the diagnostic outpatient clinics (DOCs) where an accelerated cancer diagnostic program is initiated. Various immunological and inflammatory biomarkers have been associated with cancer, including soluble urokinase plasminogen activator receptor (suPAR) and the pattern recognition receptors (PRRs) pentraxin‐3, mannose‐binding lectin, ficolin‐1, ficolin‐2 and ficolin‐3. We aimed to evaluate these biomarkers and compare their diagnostic ability to classical biomarkers for diagnosing cancer in patients with NSSC. Patients were included from the DOC, Department of Infectious Diseases, Copenhagen University Hospital Hvidovre. Patients were given a final diagnosis based on the combined results from scans, blood work and physical examination. Weight loss, Charlson score and previous cancer were registered on admission, and plasma concentrations of biomarkers were measured. The primary outcome was incident cancer within 1 year. Out of 197 patients included, 39 patients (19.8%) were diagnosed with cancer. Patients with cancer were significantly older and had a higher burden of comorbidities and previous cancer diagnoses compared to patients who were not diagnosed with cancer. Previous cancer, C‐reactive protein (CRP) and suPAR were significantly associated with newly diagnosed cancer during follow‐up in multiple logistic regression analyses adjusted for age, sex and CRP. Neither any of the PRRs investigated nor self‐reported weight loss was associated with cancer. In this study, previous cancer, CRP and suPAR were significantly associated with cancer diagnosis in patients with NSSC. Ficolin‐1‐3, MBL and pentraxin‐3 were not associated with cancer. John Wiley and Sons Inc. 2017-04-24 2017-07-01 /pmc/articles/PMC5518177/ /pubmed/28393357 http://dx.doi.org/10.1002/ijc.30732 Text en © 2017 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of Union for International Cancer Control This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Tumor Markers and Signatures Rasmussen, Line Jee Hartmann Schultz, Martin Gaardsting, Anne Ladelund, Steen Garred, Peter Iversen, Kasper Eugen‐Olsen, Jesper Helms, Morten David, Kim Peter Kjær, Andreas Lebech, Anne‐Mette Kronborg, Gitte Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer |
title | Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer |
title_full | Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer |
title_fullStr | Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer |
title_full_unstemmed | Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer |
title_short | Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer |
title_sort | inflammatory biomarkers and cancer: crp and supar as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer |
topic | Tumor Markers and Signatures |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518177/ https://www.ncbi.nlm.nih.gov/pubmed/28393357 http://dx.doi.org/10.1002/ijc.30732 |
work_keys_str_mv | AT rasmussenlinejeehartmann inflammatorybiomarkersandcancercrpandsuparasmarkersofincidentcancerinpatientswithseriousnonspecificsymptomsandsignsofcancer AT schultzmartin inflammatorybiomarkersandcancercrpandsuparasmarkersofincidentcancerinpatientswithseriousnonspecificsymptomsandsignsofcancer AT gaardstinganne inflammatorybiomarkersandcancercrpandsuparasmarkersofincidentcancerinpatientswithseriousnonspecificsymptomsandsignsofcancer AT ladelundsteen inflammatorybiomarkersandcancercrpandsuparasmarkersofincidentcancerinpatientswithseriousnonspecificsymptomsandsignsofcancer AT garredpeter inflammatorybiomarkersandcancercrpandsuparasmarkersofincidentcancerinpatientswithseriousnonspecificsymptomsandsignsofcancer AT iversenkasper inflammatorybiomarkersandcancercrpandsuparasmarkersofincidentcancerinpatientswithseriousnonspecificsymptomsandsignsofcancer AT eugenolsenjesper inflammatorybiomarkersandcancercrpandsuparasmarkersofincidentcancerinpatientswithseriousnonspecificsymptomsandsignsofcancer AT helmsmorten inflammatorybiomarkersandcancercrpandsuparasmarkersofincidentcancerinpatientswithseriousnonspecificsymptomsandsignsofcancer AT davidkimpeter inflammatorybiomarkersandcancercrpandsuparasmarkersofincidentcancerinpatientswithseriousnonspecificsymptomsandsignsofcancer AT kjærandreas inflammatorybiomarkersandcancercrpandsuparasmarkersofincidentcancerinpatientswithseriousnonspecificsymptomsandsignsofcancer AT lebechannemette inflammatorybiomarkersandcancercrpandsuparasmarkersofincidentcancerinpatientswithseriousnonspecificsymptomsandsignsofcancer AT kronborggitte inflammatorybiomarkersandcancercrpandsuparasmarkersofincidentcancerinpatientswithseriousnonspecificsymptomsandsignsofcancer |